Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149963 | 1.00 | SMYD2 (0.39) | SMYD2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL1293220 | 1.00 | SMYD2 (0.39) | SMYD2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL15348613 | 0.92 | SMYD2 (0.38) | SMYD2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL15348614 | 0.92 | SMYD2 (0.38) | SMYD2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL30141492 | 0.92 | SMYD2 (0.38) | SMYD2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL31048362 | 0.91 | SMYD2 (0.37) | SMYD2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL9558683 | 0.84 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL9558690 | 0.84 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL14285577 | 0.84 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL15209526 | 0.81 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565587-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B Technologies (Beijing) Co., Limited (CN) | 2025-06-11 | — | — | EP | disclosed |
| US-20250154153-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) | 2025-05-15 | — | — | US | disclosed |
| WO-2025076235-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | Redona Therapeutics, Inc. | 2024-08-01 | — | — | US | disclosed |
| WO-2024027116-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) | 2024-02-08 | — | — | WO | disclosed |
| CN-116157392-A | Compounds targeting RNA binding proteins or RNA modification proteins | 雷多纳治疗公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-4114831-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | Twentyeight-Seven, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| EP-2729445-B1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-10-21 | — | — | EP | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| US-7314940-B2 | For therapy and prophylaxis of neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| WO-2005007083-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154153-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | PLA2G4A, PLA2G1B, PLA2G4B | SMYD2 3354/4885GABRA1 4666/4885GABRG2 4585/4885 |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | SMYD2 3189/4885GABRA1 2140/4885GABRG2 2920/4885 |
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | NSUN3, NSUN2, RBM3 | SMYD2 686/4885GABRA1 3173/4885GABRG2 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.